Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow HLSQ by emailGet an email when HLSQ pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HLSQ, unsubscribe in one click. Privacy
📣 What HLSQ Says Is Next
by 2030 · “Market expected to reach $37.84 billion by 2030 https://www.grandviewresearch.com/industry-analysis/video-analytics-market $37.84 B $12.71 B 2025 2030 Critical Infrastructure Protection Rail, transportation, industrial, energy, and sensitive sites.”
Company press release, Jun 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full HLSQ picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HLSQ and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.